Eventide Asset Management’s ADC Therapeutics ADCT Stock Holding History

Eventide Asset Management’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,701,655	Closed	-$21.4M	–	302
2026 Q1	$21.4M	Buy	5,701,655 +2,337,588	+69%	+$9.22M	0.35%	100
2025 Q4	$11.9M	Buy	+3,364,067	New	+$13.7M	0.19%	134
2023 Q2	–	Sell	-1,675,959	Closed	-$3.27M	–	140
2023 Q1	$3.27M	Sell	1,675,959 -204,000	-11%	-$753K	0.06%	131
2022 Q4	$7.22M	Hold	1,879,959	–	–	0.14%	119
2022 Q3	$9.06M	Hold	1,879,959	–	–	0.18%	106
2022 Q2	$14.9M	Sell	1,879,959 -95,041	-5%	-$899K	0.32%	81
2022 Q1	$29M	Hold	1,975,000	–	–	0.45%	67
2021 Q4	$39.9M	Buy	1,975,000 +663,010	+51%	+$16M	0.51%	68
2021 Q3	$35.6M	Hold	1,311,990	–	–	0.47%	69
2021 Q2	$31.9M	Buy	1,311,990 +397,251	+43%	+$9.22M	0.43%	70
2021 Q1	$22.3M	Sell	914,739 -160,261	-15%	-$4.64M	0.33%	89
2020 Q4	$34.4M	Buy	1,075,000 +494,517	+85%	+$16.2M	0.53%	62
2020 Q3	$19.1M	Buy	580,483 +430,483	+287%	+$18.6M	0.37%	77
2020 Q2	$7.02M	Buy	+150,000	New	+$5.69M	0.15%	100

Other funds holding ADCT

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Eventide Asset Management's ADCT Position: Q2 2026 in Review

Eventide Asset Management sold out of ADC Therapeutics (ADCT) in Q2 2026, closing a stake of 5,701,655 shares — an estimated $21.4M sold.

Eventide Asset Management first reported a position in ADCT in Q2 2020 and held it in 14 quarters. The position peaked at $39.9M in Q4 2021. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

Eventide Asset Management reported no remaining ADC Therapeutics position as of Q2 2026 after selling out during the quarter.
Eventide Asset Management sold 5,701,655 ADC Therapeutics shares in Q2 2026, an estimated $21.4M.
Eventide Asset Management first reported a position in ADC Therapeutics in Q2 2020 and held it in 14 quarters.
Eventide Asset Management's ADC Therapeutics position peaked at $39.9M in Q4 2021.
114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.